NCT06871644Not yet recruiting
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
CD7CAR-T Cell Therapy As a Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study
Source: ClinicalTrials.gov · Last updated 12 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 27 Feb 2025
- Start date
- 18 Mar 2025
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT06871644
What you commit to
- Study type: Interventional
- Planned participants: 18
- From 18 Mar 2025 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Malignancy other than AID disease within 5 years prior to screening Hepatitis B surface antigen (HBsAg) positive, AIDS, syphilis and other virus positive persons Severe heart disease
Who the study is looking for
- \- Diagnosed relapsing/refractory systemic sclerosis that has failed treatment with at least two immunosuppressive and/or biologic agents.
- Bone marrow and coagulation function, liver and kidney function, cardiopulmonary function are satisfied No serious mental disorders
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PersonGen Anke Cellular Therapeutice Co,Ltd. Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.